Almac Group, a Craigavon, Ireland-based contract development and manufacturing organization, has successfully completed an inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of its new pharmaceutical development and manufacturing facilities at Charnwood Campus, Loughborough, England.

In November 2015, Almac Group announced the expansion of its pharmaceutical development and manufacturing services with the acquisition of a proportion of the 70-acre Charnwood Campus in Loughborough, a science, technology, and enterprise park. Since that announcement, the facilities have undergone investment both in building enhancements and the installation and validation of new processing and analytical technology.

This successful MHRA inspection provides Almac with the necessary licenses to develop, manufacture, and pack non-potent and potent, solid oral drug products for clinical trials and commercial supply at the Charnwood site. Existing development and GMP services are offered from the company’s Craigavon headquarters.

Source: Almac Group